Clinical Trials on Influenza Type A

Total 62688 results

The University of Hong Kong

Withdrawn

Novel Assays for Detection of Influenza Virus

Influenza A Virus

Hong Kong
GlaxoSmithKline

Completed

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days (NAI113625)

Influenza A Virus, H1N1 Subtype

United States
St. Jude Children's Research Hospital
American University of Beirut Medical Center

Completed

Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon

A/H1N1 Influenza | Swine Flu

Lebanon
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
CytoPharm, Inc.

Completed

Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment

Influenza A Virus Infection

Taiwan
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza

Influenza A Virus Infection

United States
Biomedical Advanced Research and Development Authority

Completed

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Influenza A Virus, H5N1 Subtype

United States
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response (HIPCVAX-010S)

Influenza A Subtype H5N1 Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults

Influenza A Subtype H7N7 Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months

Influenza | Swine-origin A/H1N1 Influenza

Finland
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults

Influenza | Swine-origin A/H1N1 Influenza

France
Sanofi

Completed

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
Celltrion

Terminated

A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A Infection

Influenza A

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Completed

Blood and Plasma Collection For Use in Future Clinical Trials

Influenza A Virus Infection

United States
Genentech, Inc.

Completed

A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

Influenza A

United States, Spain, Korea, Republic of, United Kingdom, Canada, New Zealand, South Africa
Novartis Vaccines

Completed

Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

Orthomyxoviridae Infections | Pandemic Influenza | Influenza A Virus Infection

Belgium
Novartis Vaccines

Completed

Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine

Swine-Origin Influenza A H1N1 Virus

Japan
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

Influenza | Swine-origin A/H1N1 Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.

Prophylaxis of A/H3N2v Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years

Influenza | Swine-origin A/H1N1 Influenza

Finland
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

France
South East Asia Infectious Disease Clinical Research...
Wellcome Trust

Completed

Antiviral Therapy for Influenza A H1N1 (SEA032)

Influenza A Virus Infection

Vietnam
Beijing Ditan Hospital
China Academy of Chinese Medical Sciences; Beijing University of Chinese Medicine and other collaborators

Unknown

A Pragmatic Randomized Controlled Trial of Chinese Herbal Medicine for Severe Pandemic H1N1 Influenza (200907001-2A)

Influenza A Virus, H1N1 Subtype

China
Institut National de la Santé Et de la Recherche...

Unknown

Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff. (FLU-HOP)

Influenza A Virus, H1N1 Subtype

France
Centers for Disease Control and Prevention, China

Unknown

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month

Influenza | Swine-origin A/H1N1 Influenza

China
Novartis Vaccines

Completed

Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China

Haemophilus Influenzae Type b (Hib) Infection

China
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

Influenza A Virus

Belgium
Hospital Clinica Nova

Terminated

Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml

Covid19 | Influenza A | H1N1 Influenza | Influenza B

Mexico
National Institute of Allergy and Infectious Diseases...

Completed

A Pilot Study for Collection of Anti-Influenza A Immune Plasma

Influenza A Virus Infection | Swine Flu

United States
Sanofi Pasteur, a Sanofi Company

Completed

Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults

Influenza | Swine-Origin A/H1N1 Influenza Virus

France
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
National Institute of Allergy and Infectious Diseases...

Completed

VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old

Influenza A Virus, H1N1 Subtype | Novel Swine-Origin

United States
Abbott Rapid Dx

Completed

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel

COVID-19 | Influenza A | Influenza B

United States
GlaxoSmithKline

Completed

Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis | Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Thailand, Philippines
Hospices Civils de Lyon

Terminated

Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection (Combina)

Influenza A Infection

France
National Institute of Allergy and Infectious Diseases...

Completed

Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers

Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2

United States
Medical Group Care, LLC
CSSi Life Sciences

Completed

MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study

COVID-19 | Influenza A | Influenza B

United States
LumiraDx UK Limited

Suspended

Performance Evaluation of the LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B Tests at Point of Care (POC) Sites (PURSUE)

COVID-19 | SARS-CoV-2 | Influenza A | Influenza B

United States
Altimmune, Inc.

Completed

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Influenza A Subtype H5N1 Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children

Influenza | Orthomyxoviridae Infections | Influenza A Virus Infection

Thailand
GlaxoSmithKline

Completed

Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis | Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Thailand
Novartis Vaccines

Completed

Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China

Haemophilus Influenzae Type b (Hib) Infection

China
Aptitude Medical Systems
Biomedical Advanced Research and Development Authority

Recruiting

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

SARS-CoV-2 Infection | Influenza A | Influenza B

United States
Thermo Fisher Scientific, Inc
NAMSA

Completed

Project STARFISH - PRJ0002679 (STARFISH)

SARS-CoV-2 Infection | Influenza A | RSV Infection | Influenza Type B

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni

Poland
GlaxoSmithKline

Completed

Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

India
The University of Hong Kong
Queen Elizabeth Hospital, Hong Kong; Queen Mary Hospital, Hong Kong; Pamela Youde... and other collaborators

Completed

H-IVIG Treatment for Severe H1N1 2009

Novel 2009 Influenza A (H1N1) Infection

Hong Kong
South East Asia Infectious Disease Clinical Research...
University of Oxford; Wellcome Trust

Completed

Host Genetic Susceptibility to Avian Influenza A/H5N1

Influenza A Virus/H5N1 Subtype

Vietnam

Clinical Trials on Influenza Type A

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations